The Omicron variant of the coronavirus does not have a negative effect on cardiovascular health in young adults who have been vaccinated, a small study suggests. Additionally, women should not delay routine mammograms after receiving a COVID-19 mRNA vaccine, experts now say.
Drugmakers Pfizer Inc and BioNTech SE said on May 23 that three doses of their COVID-19 vaccine generated a strong immune response in children under age 5 and was safe and well-tolerated in their clinical trial.
Report: Pfizer, NIH Discussing Study of Longer Paxlovid Dosing Regimen
Antivirals, Clinical Trials, COVID-19 cases, COVID-19 Studies, COVID-19 Therapeutics, Dr. Anthony Fauci (Director), Emergency Use Authorization (EUA), National Institutes of Health, Omicron (B.1.1.529) (South Africa), Paxlovid, Pfizer, R&D, TherapeuticsWith increasing concerns about COVID-19 reinfection, Pfizer and the National Institutes of Health are discussing potential studies regarding a longer treatment period with the antiviral medication Paxlovid.
Why Pfizer May Be Holding Paxlovid Close to the Chest
Antivirals, Bloomberg, Clinical Trials, COVID-19 Therapeutics, Drugs for Neglected Diseases Initiative (DNDi), FDA, Hospitalized COVID-19 Patients, Merck, Molnupiravir, Paxlovid, Pfizer, R&D, Symptoms: Coronavirus Disease 2019 (COVID-19), TherapeuticsReportedly, Pfizer is holding the company’s COVID-19 antiviral therapy Paxlovid under tight control. This is a disappointment to numerous investigators who want to test the antiviral combination therapy with other drugs in case the virus develops resistance to the combo.
Study: mRNA vaccines perform better against COVID-19 variants of concern
AstraZeneca, BNT162b2 (Pfizer and BioNTech), Coronavirus Disease (COVID-19) Pandemic, COVID-19 Studies, COVID-19 Vaccines, Covid-19 Variants, Janssen, Janssen COVID-19 Vaccine (J&J), Johnson & Johnson, Messenger RNA (mRNA) Vaccines, Moderna, mRNA-1273/Moderna COVID-19 Vaccine (Moderna), Pandemics, Peer-Reviewed Analysis, Pfizer, PLOS Medicine, R&D, SARS-CoV-2 virus, Therapeutics, Vaxzevria (previously COVID-19 Vaccine AstraZeneca)In a peer-reviewed study published May 17 in PLOS Medicine, scientists found that mRNA-based COVID-19 vaccines were superior to adenovirus vector-based ones across major variants of the SARS-CoV-2 virus.
As U.S. COVID-19 cases rise, so does demand for antivirals
Antivirals, Apple, BNT162b2 (Pfizer and BioNTech), CDC, Connecticut, COVID-19 booster shots, COVID-19 cases, COVID-19 Therapeutics, COVID-19 Vaccines, Delaware, Department of Health and Human Services (HHS), Emergency Use Authorization (EUA), FDA, Health Officials, Hospitalized COVID-19 Patients, Maine, Massachusetts, Merck, Molnupiravir, New York, Northeast, Omicron (B.1.1.529) (South Africa), Omicron BA.2, Paxlovid, Pfizer, Regions, Reuters Tally, Rhode Island, Therapeutics, U.S. government, United States, White HouseRising COVID-19 cases are driving up the use of therapeutics, with Pfizer Inc.’s oral antiviral treatment Paxlovid seeing a 315 percent jump over the past four weeks, U.S. health officials said on May 17.
U.S. FDA authorizes Pfizer’s COVID booster shot for young children
BNT162b2 (Pfizer and BioNTech), Children 5-11 Years, Coronavirus Disease (COVID-19) Pandemic, COVID-19 booster shots, COVID-19 shots, COVID-19 Vaccinations, COVID-19 Vaccines, Emergency Use Authorization (EUA), FDA, Pandemics, Pediatric, Pediatric Vaccines, Pfizer, Therapeutics, VaccinationsThe U.S. Food and Drug Administration on May 17 authorized the use of a booster shot of Pfizer and BioNTech’s COVID-19 vaccine for children aged 5 to 11, making everyone in the United States over the age of 5 eligible for a third shot.
FDA authorizes COVID-19 boosters for kids 5-11 as cases creep up
Antidepressants, BNT162b2 (Pfizer and BioNTech), Coronavirus Disease (COVID-19) Pandemic, Coronavirus Vaccines, COVID-19 cases, COVID-19 Deaths, COVID-19 Vaccines, Death Tolls, Fluvoxamine, Generics, Health Outcomes, Healthcare Economics Outcomes Resesarch, Pandemics, Patient Deaths, Pfizer, SARS-CoV-2 virus, TherapeuticsOn May 17, the U.S. FDA authorized a booster of Pfizer’s vaccine for kids ages 5 to 11 years. The action comes as major cities are announcing a rise in cases. Additionally, COVID-19 would have claimed over 110,000 more lives in 2021 if not for the Pfizer-BioNTech vaccine, according to a Pfizer-sponsored report on the first year of the U.S. vaccination program.
Generic drugmakers to sell Pfizer’s Paxlovid for $25 or less in low-income countries
Clinton Health Access Initiative (CHAI), COVID-19 Therapeutic, COVID-19 Therapeutics, COVID-19 Therapies, Drug Pricing, Generic Substitution, Generics, Low-Income Countries, Medicines Patent Pool, Middle-Income Countries, Pfizer, Therapeutics, United NationsSeveral generic drugmakers that will produce versions of Pfizer’s COVID-19 antiviral treatment Paxlovid agreed to sell the medicine in low-income and middle-income countries for $25 a course or less, the Clinton Health Access Initiative (CHAI) said on May 12.
Pfizer Inc.’s $11.6 billion deal for migraine specialist Biohaven Pharmaceutical has kindled expectations on Wall Street that the transaction may usher in more buyouts as cash-flush drugmakers look to snap up beaten-down smaller biotechs.